News ArchivesRead News
Naltrexone May Diminish Impulse Control Disorders in Parkinson's Disease Patients
Wednesday July 30, 2014
Medical Xpress - Up to 20 percent of Parkinson's disease (PD) patients and their families may confront a common but largely unrecognized challenge: the occurrence of impulse control disorders (ICDs) such as compulsive gambling, sexual behavior, eating, or spending. Yet the presence of PD in these patients can severely limit or complicate treatment options. A team of investigators from the Perelman School of Medicine at the University of Pennsylvania and the Parkinson's Disease Research, Education and Clinical Center (PADRECC) at the Philadelphia Veterans Affairs Medical Center conducted a pilot study and found that the opioid antagonist naltrexone may be an effective treatment for diminishing ICD symptoms in PD patients. The results were published in the journal Neurology.
Researchers believe that these issues may arise as a result of medications used to treat the disease, but also could be a result of the disease itself, or a combination of both. ICDs can create financial, personal, employment, and social problems that add to the burden on patients and caregivers whose lives are already devastated by PD.
A sample of 50 PD patients, all of whom began displaying their ICD symptoms after both the onset of PD and the initiation of dopamine agonist treatment (which was continued normally during the course of the study) were placed on a placebo-controlled flexible dose of naltrexone, 50-100 mg/day.
Naltrexone was FDA approved for the treatment of alcohol dependence in 1994. Since then, a number of studies have confirmed its efficacy in reducing frequency and severity of relapse to drinking. It is less commonly used in the treatment of opioid addiction and rapid detoxification.
Patients were assessed by several evaluation measures, chiefly the Clinical Global Impression-Change (CGI-C), which was completed by a clinician, and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS), developed by the research team and completed by the patient. Several other assessment tools were used to evaluate PD symptoms and other psychological responses.
The outcome of the eight-week study was not definitive, reports lead author Daniel Weintraub, MD, an assistant professor of Psychiatry and a Fellow in Penn's Institute on Aging. "On the primary outcome measure (the CGI-C), we did not see a benefit in terms of the medication," he says. However, on the secondary measure (the QUIP-RS), "we did see a benefit of treatment, suggesting at least on a self-rated measure of ICD severity that naltrexone did help diminish the severity of ICD symptoms in PD patients."
Weintraub explains, "The interesting thing is that ICDs may not be specific to PD at all, but only to the medication which happens to be used primarily in PD patients. It may not be a disease effect as opposed to just excessive dopamine stimulation of a particular type. These PD medications are very potent medications for the D2 subset of dopamine receptors in the brain, and it seems that if you stimulate or overstimulate those, people may develop these problems whether or not they have PD."
Weintraub and his colleagues believe that the small size of the study and the inherent differences in interpreting an outcome measure based on a global rating such as the CGI-C compared to a continuous measure of symptom severity such as the QUIP-RS may limit their results.
Weintraub says this pilot study is a promising first step in identifying ICD treatments for PD patients, and potentially, improving their quality of life. "It shows that it is possible to do a randomized controlled trial for this problem in PD, which is an important point," he notes. "It shows that you have to think carefully about the primary outcome measures. And I think it supports further study of medications like naltrexone and other opioid antagonists with a larger, more definitive clinical trial."
(30 July 2014). Medical Xpress.Naltrexone May Diminish Impulse Control Disorders in Parkinson's Disease Patients. http://medicalxpress.com/news/2014-07-naltrexone-diminish-impulse-disorders-parkinson.html
Recent NewsJan 2 - January 2, 2018 News Update
Dec 26 - December 26, 2017 News Update
Dec 19 - December 19, 2017 News Update
Dec 8 - New technique scours the genome for genes that combat disease
Dec 8 - Restless sleep may be an early sign of Parkinson's, dementia
Dec 1 - Defects in cell's 'waste disposal system' linked to Parkinson's
Dec 1 - Dual virtual reality/treadmill exercises promote brain plasticity in Parkinson's patients
Nov 17 - 'Moving Day' participant is not letting young-onset Parkinson's disease stop him
Nov 17 - Focused ultrasound shows promise for treating Parkinson's tremor
Nov 17 - New research to target air pollution as a potential trigger for Parkinson’s
Nov 17 - This device will let you feel what it's like to suffer from Parkinson's
Nov 10 - How does Parkinson's disease influence depression?
Nov 10 - House votes to repeal ObamaCare's Medicare cost-cutting board
Nov 10 - Microsoft shows off watch that quiets Parkinson's tremors
Nov 3 - Utah group battling Parkinson's disease with boxing
Nov 3 - UVA-LED STUDY EXAMINES POTENTIAL OF SOUND WAVES TO MANAGE PARKINSON’S DISEASE
Oct 27 - Herbicide's link to Parkinson's disease
Oct 27 - NTU Singapore, KAIST scientists discover new mechanism that causes Parkinsonian symptoms
Oct 27 - 70,000 Washingtonians face higher insurance costs after Trump order, officials say
Oct 18 - Brain disconnections may contribute to Parkinson's hallucinations